MX350463B - Métodos de tratamiento del dolor. - Google Patents

Métodos de tratamiento del dolor.

Info

Publication number
MX350463B
MX350463B MX2014000744A MX2014000744A MX350463B MX 350463 B MX350463 B MX 350463B MX 2014000744 A MX2014000744 A MX 2014000744A MX 2014000744 A MX2014000744 A MX 2014000744A MX 350463 B MX350463 B MX 350463B
Authority
MX
Mexico
Prior art keywords
methods
treating pain
directed
subject matter
disclosed subject
Prior art date
Application number
MX2014000744A
Other languages
English (en)
Spanish (es)
Other versions
MX2014000744A (es
Inventor
Daniel B Carr
Peter Lacouture
Garcia De Rocha Marcelo
Original Assignee
Hospira Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hospira Inc filed Critical Hospira Inc
Publication of MX2014000744A publication Critical patent/MX2014000744A/es
Publication of MX350463B publication Critical patent/MX350463B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2014000744A 2011-07-20 2012-07-19 Métodos de tratamiento del dolor. MX350463B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161509886P 2011-07-20 2011-07-20
PCT/US2012/047453 WO2013013076A1 (en) 2011-07-20 2012-07-19 Methods of treating pain

Publications (2)

Publication Number Publication Date
MX2014000744A MX2014000744A (es) 2014-05-14
MX350463B true MX350463B (es) 2017-09-06

Family

ID=47558482

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014000744A MX350463B (es) 2011-07-20 2012-07-19 Métodos de tratamiento del dolor.

Country Status (16)

Country Link
US (1) US20140221490A1 (enExample)
EP (2) EP3257505A1 (enExample)
JP (2) JP6320917B2 (enExample)
KR (1) KR20140063583A (enExample)
CN (1) CN103781484A (enExample)
AU (1) AU2012283915B2 (enExample)
BR (1) BR112014001335A2 (enExample)
CA (1) CA2841964A1 (enExample)
DK (1) DK2734212T3 (enExample)
ES (1) ES2646226T3 (enExample)
IL (1) IL230433A0 (enExample)
IN (1) IN2014CN00315A (enExample)
MX (1) MX350463B (enExample)
MY (1) MY166036A (enExample)
NO (1) NO2854815T3 (enExample)
WO (1) WO2013013076A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2522343A1 (en) * 2006-03-28 2012-11-14 Javelin Pharmaceuticals, Inc. Formulations of Low Dose Diclofenac and Beta-Cyclodextrin
JP5646320B2 (ja) 2007-05-11 2014-12-24 アダイニクス, インコーポレイテッド 遺伝子発現と疼痛
PL2220030T3 (pl) 2007-11-06 2016-07-29 Bioelectron Tech Corp Pochodne 4-(p-chinonylo)-2-hydroksybutanamidu do leczenia chorób mitochondrialnych
RU2668136C2 (ru) 2012-05-10 2018-09-26 Эйдинкс, Инк. Композиции для доставки активных ингредиентов
US20140275261A1 (en) 2013-03-15 2014-09-18 Dr. Reddy's Laboratories, Inc. Diclofenac parenteral compositions
CN106661578B (zh) 2014-08-15 2020-08-04 埃迪恩克斯股份有限公司 用于疼痛治疗的寡核苷酸诱饵
WO2017151644A1 (en) * 2016-02-29 2017-09-08 Adynxx, Inc. Compositions and methods for pain amelioration via modification of gene expression
US20180025116A1 (en) * 2016-07-22 2018-01-25 Arizona Board Of Regents On Behalf Of University Of Arizona Clinical Event Management and Communication System
BR112020002804A2 (pt) 2017-08-24 2020-07-28 Novo Nordisk A/S composição farmacêutica líquida, e, kit
US20200027555A1 (en) * 2018-07-17 2020-01-23 Lewis Pharmaceutical Information, Inc. Patient centric drug analysis platform
IL294521A (en) * 2020-02-18 2022-09-01 Novo Nordisk As glp-1 compounds and their uses
CN111494446B (zh) * 2020-05-18 2021-08-17 深圳市宝安中医院(集团) 治疗胆绞痛的中药组合物及其应用
WO2023034293A1 (en) * 2021-08-31 2023-03-09 Ethismos Research, Inc. Methods of preventing and treating pain and associated symptoms

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4727064A (en) 1984-04-25 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Pharmaceutical preparations containing cyclodextrin derivatives
GB8506792D0 (en) 1985-03-15 1985-04-17 Janssen Pharmaceutica Nv Derivatives of y-cyclodextrin
US6407079B1 (en) 1985-07-03 2002-06-18 Janssen Pharmaceutica N.V. Pharmaceutical compositions containing drugs which are instable or sparingly soluble in water and methods for their preparation
US5002935A (en) 1987-12-30 1991-03-26 University Of Florida Improvements in redox systems for brain-targeted drug delivery
US5389681A (en) 1992-10-22 1995-02-14 Ciba-Geigy Corporation Parenteral solutions for diclofenac salts
IL111184A (en) * 1993-10-08 2000-08-13 Farmarc Nederland B V Of Cito Crystalline inclusion complex of diclofenac with unsubstituted beta-cyclodextrin
ZA949182B (en) 1993-12-02 1995-07-26 South African Druggists Ltd Pharmaceutical composition
AU2001259816A1 (en) 2000-06-22 2002-01-02 Advanced Medecine, Inc. Polyhydroxy glycopeptide derivatives
EP1467770A1 (en) 2002-01-15 2004-10-20 ALTANA Pharma AG Pantoprazole cyclodextrin inclusion complexes
US6869939B2 (en) 2002-05-04 2005-03-22 Cydex, Inc. Formulations containing amiodarone and sulfoalkyl ether cyclodextrin
US7387194B2 (en) * 2003-11-04 2008-06-17 Otis Elevator Company Automatic passenger conveyor slow speed operation
DE602004025151D1 (de) 2004-03-10 2010-03-04 Shimoda Biotech Pty Ltd Stabile injizierbare Diclofenac- Zubereitungen
EP2522343A1 (en) * 2006-03-28 2012-11-14 Javelin Pharmaceuticals, Inc. Formulations of Low Dose Diclofenac and Beta-Cyclodextrin
MX2008012496A (es) * 2006-03-28 2009-01-07 Javelin Pharmaceuticals Inc Formulaciones de farmacos anti-inflamatorios no esteroidales de baja dosis y beta-ciclodextrina.
CN101264086A (zh) 2007-03-14 2008-09-17 南京师范大学 含有头孢克肟环糊精包合物的药物组合物及其制备方法
WO2009089269A1 (en) * 2008-01-07 2009-07-16 Javelin Pharmaceuticals, Inc. Methods of treating pain while minimizing adverse effects on platelet function
US7662858B2 (en) * 2008-05-23 2010-02-16 Aaipharma, Inc. Method of treating post-surgical acute pain

Also Published As

Publication number Publication date
EP2734212A4 (en) 2014-12-24
JP6320917B2 (ja) 2018-05-09
AU2012283915A1 (en) 2014-02-06
US20140221490A1 (en) 2014-08-07
JP2014520893A (ja) 2014-08-25
DK2734212T3 (da) 2017-11-06
WO2013013076A1 (en) 2013-01-24
NO2854815T3 (enExample) 2018-04-21
CA2841964A1 (en) 2013-01-24
JP2017110022A (ja) 2017-06-22
MY166036A (en) 2018-05-21
BR112014001335A2 (pt) 2017-02-21
KR20140063583A (ko) 2014-05-27
EP2734212A1 (en) 2014-05-28
MX2014000744A (es) 2014-05-14
CN103781484A (zh) 2014-05-07
EP3257505A1 (en) 2017-12-20
ES2646226T3 (es) 2017-12-12
AU2012283915B2 (en) 2016-11-24
EP2734212B1 (en) 2017-09-06
IL230433A0 (en) 2014-03-31
IN2014CN00315A (enExample) 2015-04-03

Similar Documents

Publication Publication Date Title
MX2014000744A (es) Métodos de tratamiento del dolor.
NZ610034A (en) Prevention of adverse effects caused by cd3 specific binding domains
PH12014500075A1 (en) Pharmaceutical composition, methods for treating and uses thereof
MX377157B (es) Preparación para usarse en el tratamiento de un cáncer positivo de gd2.
NZ626954A (en) Combination therapy of antibodies against human csf-1r and uses thereof
TN2014000206A1 (en) Antibody molecules having specificity for human ox40
NZ705008A (en) Novel modulators and methods of use
MX2019001977A (es) Metodos y composiciones para tratar esclerosis multiple y trastornos relacionados.
MX356728B (es) Combinación farmacéutica para usar en el tratamiento de pacientes que padecen diabetes de tipo 2.
AU2012229123A8 (en) Methods of treating breast cancer with anthracycline therapy
MX2013007171A (es) Inductor de autofagia y terapia de combinacion inhibidora para el tratamiento de neoplasias.
MX2012000949A (es) Terapias de combinacion con moduladores de ck2.
NZ628433A (en) Chitosan-derived compositions
MX364220B (es) Metodos de tratamientos de fibrosis.
TN2012000610A1 (en) Heterocyclic compounds, their preparation and their therapeutic application
IN2014DN08385A (enExample)
BR112012006070A2 (pt) composições e métodos para tratar distúrbios convulsivos.
MX356317B (es) Tratamiento de síntomas asociados a gastroparesia femenina.
EP3449917A3 (en) Tapentadol for preventing chronification of pain
WO2012044963A3 (en) Perfluorocarbons for use in treating pruritus
MX2011007384A (es) Terapias de combinacion para trastornos neoplásticos.
MX2013012967A (es) Composicion de miel con l-alanil-l-glutamina.
TN2014000418A1 (en) Methods for treating cancer using pi3k inhibitor and mek inhibitor
MX2014006990A (es) Tratamiento para diabetes tipo i y tipo ii.
MX364643B (es) USO DEL COMPUESTO FTY720: 2-amino - 2-[2-(4-octilfenil) etil] propano-1,3-diol (fingolimod) EN EL TRATAMIENTO DE PACIENTES CON DIABETES DE TIPO 2.

Legal Events

Date Code Title Description
FG Grant or registration